Navigation Links
P&G Response to FDA Approval of Prevacid OTC(R) 24HR
Date:5/14/2009

CINCINNATI, May 14 /PRNewswire/ -- In response to the FDA's approval of Prevacid OTC(R) 24HR, The Procter & Gamble Company issued the following statement:

(Photo: http://www.newscom.com/cgi-bin/prnh//NY17325 )

"Prilosec OTC(R) is the #1 doctor and pharmacist recommended over-the-counter heartburn remedy in the U.S.," said Tim Brown - General Manager, P&G Personal Health Care North America. "Procter & Gamble built the OTC PPI market and since 2003, millions of consumers have made Prilosec OTC their frequent heartburn remedy of choice. We don't expect that to change given our strong record of providing all day and all night heartburn relief with just one pill a day."

Procter & Gamble (P&G) is a leader in gastrointestinal health and is committed to meeting the needs of its consumers with innovative digestive wellness treatments, including top-selling brands such as ALIGN(R), ASACOL(R), METAMUCIL(R), PRILOSEC OTC(R) and PEPTO-BISMOL(R).

About PRILOSEC OTC

PRILOSEC OTC is the #1 Doctor recommended acid reducer+ and Pharmacist recommended OTC Heartburn medicine++, the first of a class of OTC heartburn medicines that treats frequent heartburn with just one pill a day, unlike most over the counter heartburn medication. Prilosec OTC is the only OTC leading heartburn medicine that can work for 24 hours with one pill a day by directly shutting down many acid pumps in your stomach when used as directed for 14 days for the treating of frequent heartburn. PRILOSEC OTC is the #1 selling OTC heartburn medicine* on the market. For more information about PRILOSEC OTC, visit www.prilosecotc.com. PRILOSEC OTC is available over-the-counter through an alliance between P&G and AstraZeneca.

About Procter & Gamble (NYSE: PG)

Three billion times a day, P&G brands touch the lives of people around the world. P&G has one of the strongest portfolios of quality, leadership brands in consumer health and wellness, including Actonel(R), Align(R), Always(R), Asacol(R), Crest(R), Enablex(R), Metamucil(R), Oral-B(R), Pepto-Bismol(R), Prilosec OTC(R), Scope(R), Tampax(R), and Vicks(R), in addition to its trusted consumer brands, including Ariel(R), Braun(R), Bounty(R), Charmin(R), Dawn(R), Downy(R), Duracell(R), Folgers(R), Gillette(R), Head & Shoulders(R), Iams(R), Lenor(R), Mach3(R), Olay(R), Pantene(R), Pampers(R), Pringles(R), Tide(R), Wella(R), and Whisper(R). The P&G community consists of over 135,000 employees working in over 80 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.

    Contact:
    P&G Health Care External Relations
    Carlos Taveras
    513-622-4645
    Taveras.cm@pg.com

    MS&L Worldwide
    Robyn Finker
    212-468-3879
    Robyn.Finker@mslworldwide.com

++ Pharmacy Times, OTC Supplement, June 2007

* Wolters Kluwer Health, Wolters Kluwer Health Physician Recommendation Audit (April 2004-June 2007, Acid Reducer Category). Data on file.


'/>"/>
SOURCE Procter & Gamble
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Study identifies key player in the bodys immune response to chronic stress
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Merck & Co., Inc. Response to Todays New York Medicaid Suit
6. Maternal depression and controlling behavior associated with increased stress response in infants
7. Family history of alcoholism affects response to drug used to treat heavy drinking
8. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
9. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month ... bleeding gums in Vancouver, BC, may be developing gingivitis, the first stage of ... and diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants in the ... finding product improvements that could reduce the occurrence of unplanned extubations (UEs). ... breathing or to provide medication. Sometimes, patient movement can cause unplanned extubations which ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage ... featuring seven new products designed to create tailored looks and athleisure-inspired outfits. UA Flex ... cotton easy care stretch twill. , With trendy looks hitting the medical community, UA ...
(Date:6/20/2017)... ... , ... John D'Eri, CEO of Rising Tide Car Wash , will ... during the Autism Society of America 's 49th annual conference to be held ... (DJFF) was founded in 2002 as the nation's first autism organization focused exclusively ...
(Date:6/20/2017)... ... June 20, 2017 , ... International water ... The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health ... world’s water crisis and how it affects the human eyes. , According ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. ... focused on the design, manufacture, sale and distribution of ... on the progress of its commercial roll-out in ... available in more than one hundred (100) medical institutions ... AeroForm offers a needle-free alternative for women who ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: